84
Participants
Start Date
April 7, 2020
Primary Completion Date
June 5, 2024
Study Completion Date
June 1, 2026
tamoxifen, letrozole, anastrozole, or exemestane
choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
Patient reported outcomes
"Questionnaire inquiries include the following:~* how cancer affects daily living~* beliefs about medicines and sensitivity to medicine~* symptoms~* adherence to endocrine therapy~* general health and well being~* depression and anxiety~* preference regarding radiation therapy"
University of Virginia, Charlottesville
Virginia Commonwealth University Massey Cancer Center, Richmond
National Cancer Institute (NCI)
NIH
Shayna Showalter, MD
OTHER